Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1974 1
1975 1
1977 1
1978 1
1987 1
1990 4
1991 1
1992 2
1993 1
1994 5
1995 2
1998 2
1999 4
2000 1
2001 1
2002 4
2003 10
2004 7
2005 5
2006 9
2007 2
2008 11
2009 6
2010 12
2011 14
2012 15
2013 21
2014 20
2015 26
2016 18
2017 15
2018 28
2019 15
2020 24
2021 23
2022 30
2023 21
2024 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

318 results

Results by year

Filters applied: . Clear all
Page 1
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome.
Trautmann A, Boyer O, Hodson E, Bagga A, Gipson DS, Samuel S, Wetzels J, Alhasan K, Banerjee S, Bhimma R, Bonilla-Felix M, Cano F, Christian M, Hahn D, Kang HG, Nakanishi K, Safouh H, Trachtman H, Xu H, Cook W, Vivarelli M, Haffner D; International Pediatric Nephrology Association. Trautmann A, et al. Pediatr Nephrol. 2023 Mar;38(3):877-919. doi: 10.1007/s00467-022-05739-3. Epub 2022 Oct 21. Pediatr Nephrol. 2023. PMID: 36269406 Free PMC article. Review.
Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic Syndrome.
Iijima K, Sako M, Oba M, Tanaka S, Hamada R, Sakai T, Ohwada Y, Ninchoji T, Yamamura T, Machida H, Shima Y, Tanaka R, Kaito H, Araki Y, Morohashi T, Kumagai N, Gotoh Y, Ikezumi Y, Kubota T, Kamei K, Fujita N, Ohtsuka Y, Okamoto T, Yamada T, Tanaka E, Shimizu M, Horinochi T, Konishi A, Omori T, Nakanishi K, Ishikura K, Ito S, Nakamura H, Nozu K; Japanese Study Group of Kidney Disease in Children. Iijima K, et al. Among authors: ishikura k. J Am Soc Nephrol. 2022 Feb;33(2):401-419. doi: 10.1681/ASN.2021050643. Epub 2021 Dec 8. J Am Soc Nephrol. 2022. PMID: 34880074 Free PMC article. Clinical Trial.
Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study.
Chan EY, Yu ELM, Angeletti A, Arslan Z, Basu B, Boyer O, Chan CY, Colucci M, Dorval G, Dossier C, Drovandi S, Ghiggeri GM, Gipson DS, Hamada R, Hogan J, Ishikura K, Kamei K, Kemper MJ, Ma AL, Parekh RS, Radhakrishnan S, Saini P, Shen Q, Sinha R, Subun C, Teo S, Vivarelli M, Webb H, Xu H, Yap HK, Tullus K. Chan EY, et al. Among authors: ishikura k. J Am Soc Nephrol. 2022 Jun;33(6):1193-1207. doi: 10.1681/ASN.2021111472. Epub 2022 Mar 30. J Am Soc Nephrol. 2022. PMID: 35354600 Free PMC article.
Current status of pediatric transplantation in Japan.
Nishimura N, Kasahara M, Ishikura K, Nakagawa S. Nishimura N, et al. Among authors: ishikura k. J Intensive Care. 2017 Jul 20;5:48. doi: 10.1186/s40560-017-0241-0. eCollection 2017. J Intensive Care. 2017. PMID: 28729907 Free PMC article. Review.
Rituximab in combination with cyclosporine and steroid pulse therapy for childhood-onset multidrug-resistant nephrotic syndrome: a multicenter single-arm clinical trial (JSKDC11 trial).
Nozu K, Sako M, Tanaka S, Kano Y, Ohwada Y, Morohashi T, Hamada R, Ohtsuka Y, Oka M, Kamei K, Inaba A, Ito S, Sakai T, Kaito H, Shima Y, Ishikura K, Nakamura H, Nakanishi K, Horinouchi T, Konishi A, Omori T, Iijima K. Nozu K, et al. Among authors: ishikura k. Clin Exp Nephrol. 2024 Apr;28(4):337-348. doi: 10.1007/s10157-023-02431-0. Epub 2023 Nov 27. Clin Exp Nephrol. 2024. PMID: 38010466 Free PMC article. Clinical Trial.
Unique structure of ozoralizumab, a trivalent anti-TNFα NANOBODY® compound, offers the potential advantage of mitigating the risk of immune complex-induced inflammation.
Kyuuma M, Kaku A, Mishima-Tsumagari C, Ogawa B, Endo M, Tamura Y, Ishikura KI, Mima M, Nakanishi Y, Fujii Y. Kyuuma M, et al. Among authors: ishikura ki. Front Immunol. 2023 Apr 14;14:1149874. doi: 10.3389/fimmu.2023.1149874. eCollection 2023. Front Immunol. 2023. PMID: 37122706 Free PMC article.
318 results